212 related articles for article (PubMed ID: 26689870)
1. Efficacy of ibrutinib in the treatment of Bing-Neel syndrome.
Cabannes-Hamy A; Lemal R; Goldwirt L; Poulain S; Amorim S; Pérignon R; Berger J; Brice P; De Kerviler E; Bay JO; Sauvageon H; Beldjord K; Mourah S; Tournilhac O; Thieblemont C
Am J Hematol; 2016 Mar; 91(3):E17-9. PubMed ID: 26689870
[No Abstract] [Full Text] [Related]
2. Ibrutinib for the treatment of Bing-Neel syndrome, a complication of Waldenström macroglobulinemia: Patient case report.
Hartsell L; Janes A; Larck C; Park S; Arnall JR
J Oncol Pharm Pract; 2019 Sep; 25(6):1534-1539. PubMed ID: 30760164
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome.
Mason C; Savona S; Rini JN; Castillo JJ; Xu L; Hunter ZR; Treon SP; Allen SL
Br J Haematol; 2017 Oct; 179(2):339-341. PubMed ID: 27409073
[No Abstract] [Full Text] [Related]
4. Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia.
Castillo JJ; Gustine JN; Meid K; Dubeau T; Severns P; Treon SP
Haematologica; 2018 Jul; 103(7):e307-e310. PubMed ID: 29472352
[No Abstract] [Full Text] [Related]
5. CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib.
Vos JM; Tsakmaklis N; Patterson CJ; Meid K; Castillo JJ; Brodsky P; Ganz T; Pals ST; Kersten MJ; Xu L; Yang G; Treon SP; Hunter ZR
Haematologica; 2017 Nov; 102(11):e452-e455. PubMed ID: 28798070
[No Abstract] [Full Text] [Related]
6. Ibrutinib therapy for lymphoplasmacytic lymphoma.
Helber MJ; Moore JE; Williams AM; Meacham PJ; Rothberg PG; Zent CS
Am J Hematol; 2017 Sep; 92(9):E542-E544. PubMed ID: 28543765
[No Abstract] [Full Text] [Related]
7. Efficacy of ibrutinib in a patient with transformed lymphoplasmacytic lymphoma and central nervous system involvement.
Hiemcke-Jiwa LS; Leguit RJ; Radersma-van Loon JH; Westerweel PE; Rood JJM; Doorduijn JK; Huibers MMH; Minnema MC
Leuk Lymphoma; 2018 May; 59(5):1256-1259. PubMed ID: 28849690
[No Abstract] [Full Text] [Related]
8. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients.
Treon SP; Castillo JJ; Skarbnik AP; Soumerai JD; Ghobrial IM; Guerrera ML; Meid K; Yang G
Blood; 2020 May; 135(21):1912-1915. PubMed ID: 32302379
[No Abstract] [Full Text] [Related]
9. Ibrutinib in previously treated Waldenström's macroglobulinemia.
Treon SP; Tripsas CK; Meid K; Warren D; Varma G; Green R; Argyropoulos KV; Yang G; Cao Y; Xu L; Patterson CJ; Rodig S; Zehnder JL; Aster JC; Harris NL; Kanan S; Ghobrial I; Castillo JJ; Laubach JP; Hunter ZR; Salman Z; Li J; Cheng M; Clow F; Graef T; Palomba ML; Advani RH
N Engl J Med; 2015 Apr; 372(15):1430-40. PubMed ID: 25853747
[TBL] [Abstract][Full Text] [Related]
10. Standard Dose of Ibrutinib is Effective in the Treatment of Bing-Neel Syndrome.
Plander M; Szendrei T; Vadvári Á; Iványi J
Pathol Oncol Res; 2020 Jan; 26(1):591-592. PubMed ID: 30357751
[No Abstract] [Full Text] [Related]
11. Efficacy of ibrutinib as first-line treatment of tumoral Bing-Neel syndrome.
Boudin L; Patient M; Roméo E; Bladé JS; de Jauréguiberry JP
Leuk Lymphoma; 2018 Nov; 59(11):2746-2748. PubMed ID: 29569974
[No Abstract] [Full Text] [Related]
12. Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
Lim KJC; Tam CS
Expert Rev Hematol; 2020 Dec; 13(12):1303-1310. PubMed ID: 33297772
[No Abstract] [Full Text] [Related]
13. Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes.
Abeykoon JP; Zanwar S; Ansell SM; Gertz MA; Kumar S; Manske M; Novak AJ; King R; Greipp P; Go R; Inwards D; Muchtar E; Habermann T; Witzig TE; Thompson CA; Dingli D; Lacy MQ; Leung N; Dispenzieri A; Gonsalves W; Warsame R; Kyle RA; Rajkumar V; Parikh SA; Kapoor P
Br J Haematol; 2020 Feb; 188(3):394-403. PubMed ID: 31468508
[TBL] [Abstract][Full Text] [Related]
14. Rare case of Bing-Neel syndrome treated successfully with ibrutinib.
Hashmi H; Dhanoa JS; Emmons R
BMJ Case Rep; 2019 Jun; 12(6):. PubMed ID: 31243026
[TBL] [Abstract][Full Text] [Related]
15. Ibrutinib for the treatment of Waldenström macroglobulinemia.
Chakraborty R; Kapoor P; Ansell SM; Gertz MA
Expert Rev Hematol; 2015 Oct; 8(5):569-79. PubMed ID: 26138997
[TBL] [Abstract][Full Text] [Related]
16. How we manage Bing-Neel syndrome.
Castillo JJ; Treon SP
Br J Haematol; 2019 Nov; 187(3):277-285. PubMed ID: 31430829
[TBL] [Abstract][Full Text] [Related]
17. Ibrutinib in the management of Waldenstrom macroglobulinemia.
Yosef A; Touloukian EZ; Nambudiri VE
J Oncol Pharm Pract; 2019 Mar; 25(2):434-441. PubMed ID: 29996737
[TBL] [Abstract][Full Text] [Related]
18. Resolution of Waldenström Macroglobulinemia-Associated Autoimmune Hemolysis With Ibrutinib.
Tripathi A; Steingart R
J Oncol Pract; 2016 May; 12(5):490-1. PubMed ID: 27170696
[No Abstract] [Full Text] [Related]
19. Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound.
Gustine JN; Meid K; Dubeau T; Severns P; Hunter ZR; Guang Y; Xu L; Treon SP; Castillo JJ
Am J Hematol; 2018 Aug; 93(4):511-517. PubMed ID: 29280186
[TBL] [Abstract][Full Text] [Related]
20. Ibrutinib-induced acute liver failure.
Kahn A; Horsley-Silva JL; Lam-Himlin DM; Reeder CB; Douglas DD; Carey EJ
Leuk Lymphoma; 2018 Feb; 59(2):512-514. PubMed ID: 28693376
[No Abstract] [Full Text] [Related]
[Next] [New Search]
